Product vision
  • Intermittent preventive treatment during pregnancy (IPTp)
  • Intermittent preventive treatment of infants (IPTi)
  • 3 tablets of 500 mg sulfadoxine - 25 mg pyrimethamine (SP; dosed via three tablets), to be given at the beginning of the 2nd trimester of pregnancy until delivery
  • WHO affirmed the effectiveness of IPTp using SP (IPTp-SP), including in areas with SP resistance
  • Estimates indicate that a full course of IPTp-SP decreases the incidence of low birth weight babies by 29%, severe maternal anaemia by 38%, and neonatal mortality by 31%. It is also one of the few health interventions showing reductions in neonatal mortality
Key features
  • Adapted SP packaging to ensure correct use and to improve perception and uptake
  • Delivery of IPTp requires a functioning antenatal care platform and access to quality-assured SP
  • Improving quality perceptions about SP and expanding access through community health worker channels can increase IPTp coverage
  • Bioequivalence study completed in 2020
  • Dossier submitted to WHO Prequalification 
Next milestone
  • WHO prequalification
  • Development of dispersible 250 mg sulphadoxine-12.5 mg pyrimethamine for intermittent preventive treatment for infants (IPTi)
MMV Project Director
  • Pierre Hugo